Key facts
- What it is: nicotinamide adenine dinucleotide (NAD+), a redox coenzyme found in every living cell; sold via the precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR)
- Class: NAD+ is a dinucleotide coenzyme, not a peptide, hormone, or growth factor. NMN is a nucleotide; NR is a form of vitamin B3
- Mechanism: NAD+ shuttles electrons in energy metabolism and is a substrate for sirtuins, PARPs, and CD38; tissue levels decline with age
- Commercial forms: NR was commercialized as Niagen; NMN research was driven largely by academic aging labs. No single approved product
- Approval status: no NAD+, NMN, or NR product is an FDA-approved drug. NR is sold as a dietary ingredient; the FDA declared NMN lawful in supplements in 2025 after excluding it in 2022. IV NAD+ is offered off-label, not approved
- Evidence level: precursors reliably raise blood NAD+; functional and anti-aging benefits in humans are modest, inconsistent, and often absent
- Reported adverse effects: generally mild — nausea, indigestion, headache, flushing; IV infusions add chest tightness and infusion-site reactions
Is NAD+ a peptide? What NAD+, NMN and NR are
NAD+ is not a peptide. It is worth saying that plainly, because searches for NAD+, NMN, and NR sit right next to searches for MOTS-c, SS-31, and epitalon in the longevity corner of the internet. Chemically they have nothing in common. A peptide is a short chain of amino acids joined by peptide bonds. NAD+ — nicotinamide adenine dinucleotide — is a coenzyme built from two nucleotides linked through a pair of phosphate groups. No amino acids, no peptide bonds.
What NAD+ does is fundamental. It is the molecule that carries electrons through the reactions that turn food into usable energy. In its oxidized form (NAD+) it accepts electrons; in its reduced form (NADH) it donates them. That NAD+/NADH cycle runs glycolysis, the citric acid cycle, and oxidative phosphorylation. Beyond metabolism, NAD+ is also consumed as a raw material by three families of enzymes: the sirtuins that regulate gene expression, the PARPs that repair DNA, and CD38, an immune enzyme. Eric Verdin's 2015 Science review lays out how central NAD+ is to aging, metabolism, and the nervous system (PubMed 26785480).
You rarely buy NAD+ itself in a capsule, because the intact molecule is large and poorly absorbed by mouth. Instead the market sells precursors — smaller building blocks your cells convert into NAD+. The two you will see most are NMN (nicotinamide mononucleotide), a nucleotide one step away from NAD+, and NR (nicotinamide riboside), a form of vitamin B3 that becomes NMN and then NAD+. Neither is a peptide, and both are the reason the NAD+ conversation exists at all.
Why NAD+ declines with age
The entire NAD+ supplement industry rests on one reasonably solid observation: tissue NAD+ falls as animals and people get older. It has been measured across worms, mice, and human tissue, and the decline shows up in skin, liver, muscle, and brain. Amjad Covarrubias and colleagues reviewed the mechanisms in a 2021 Nature Reviews Molecular Cell Biology paper (PubMed 33353981).
Two forces drive the drop. Production slows, and consumption rises. On the consumption side, the enzyme CD38 increases with age and acts as a major NAD+ drain — a 2016 Cell Metabolism study showed that age-related NAD+ decline and the mitochondrial dysfunction that follows are dictated in large part by CD38 (PubMed 27304511). PARP activity, driven by accumulating DNA damage, adds to the demand. In the brain, falling NAD+ has been tied to the same aging and neurodegenerative processes that make late-life decline hard to reverse (PubMed 31577933).
This is where honest reading matters. A molecule that declines with age and is central to metabolism is an obvious target. But "NAD+ falls as you age" is a correlation, not proof that topping it back up rewinds anything. The precursor trials exist to test that leap, and their results are more sobering than the marketing.
NAD+ precursors: NMN, NR and niacin
Your body already makes NAD+ every day, mostly from vitamin B3 through what biochemists call the salvage pathway. The forms of B3 — nicotinic acid (niacin), nicotinamide, and nicotinamide riboside — all feed in. NR converts to NMN, NMN converts to NAD+, and the cycle recycles nicotinamide released when NAD+ is consumed. The commercial precursors simply flood that existing pathway with extra raw material.
NR earned its place first because it is genuinely well absorbed by mouth. Trammell and colleagues showed in a 2016 Nature Communications study that a single oral dose of NR raised NAD+ in human blood, establishing it as orally bioavailable in people, not just cells (PubMed 27721479). NMN is chemically one step closer to NAD+, and much of the debate around it concerns whether it is absorbed intact or converted back to NR at the gut wall — a detail that matters more to biochemists than to the blood NAD+ number, which rises either way.
The older, cheaper B3 forms matter for context too: high-dose niacin reliably raises NAD+ and has decades of use, though it causes the well-known flush. David Sinclair's group summarized the landscape of NAD-boosting molecules and the animal evidence behind them in a 2018 Cell Metabolism review (PubMed 29514064). The animal data are broad and often impressive; whether they carry into humans is the question the next section answers.
Does NAD+ supplementation actually work?
Split the question in two, because the answers are very different. "Does NMN or NR raise NAD+ in people?" is one question. "Does raising NAD+ make people healthier or younger?" is another. The first has a clear yes. The second does not.
On raising NAD+, the human data are consistent. Across trials, oral NR and NMN lift blood NAD+ by roughly 40 to 100 percent within two weeks, and the rise holds with continued use. Chris Martens and colleagues showed in a 2018 Nature Communications trial that chronic NR was well tolerated and elevated NAD+ by about 60 percent in healthy middle-aged and older adults (PubMed 29599478). The number on the lab report moves. That part is real.
On what that does for you, the picture fragments. In the same Martens trial, a secondary analysis hinted at lower systolic blood pressure and aortic stiffness in participants who started with elevated readings, but this was not the primary outcome and needs confirmation. Yusuf Elhassan's 2019 Cell Reports study fed NR to older men, raised the NAD+ metabolome in their skeletal muscle, and saw an anti-inflammatory shift in gene expression — yet found no measurable improvement in mitochondrial function or exercise performance (PubMed 31412242). The NAD+ went up; the muscle did not obviously work better.
NMN has produced the most eye-catching positive result to date. Yoshino and colleagues reported in a 2021 Science paper that NMN improved skeletal-muscle insulin sensitivity in prediabetic, overweight and obese postmenopausal women (PubMed 33888596). It is a genuine functional signal — but a single, small, tightly defined study, not a general anti-aging finding. A 2023 systematic review of NMN human trials concluded that while NMN is safe and reliably raises NAD+, the antiaging and performance effects reported so far are preliminary and inconsistent (PubMed 37619764). That sentence is the honest summary of the whole field.
What NR and NMN human trials actually showed
The pattern across the better-run studies is remarkably consistent: NAD+ rises, and the functional endpoint either moves a little or not at all. The table below collects representative human trials so the gap between the biomarker and the benefit is easy to see.
| Trial / precursor | Population | Effect on NAD+ | Functional outcome |
|---|---|---|---|
| Martens 2018 — NR, ~1000 mg/day | Healthy middle-aged & older adults | NAD+ up ~60% | Well tolerated; hint of lower BP in a subgroup only |
| Elhassan 2019 — NR, 1000 mg/day | Older men | Muscle NAD+ metabolome raised | Anti-inflammatory gene shift; no gain in mitochondrial function or exercise |
| Yoshino 2021 — NMN, 250 mg/day | Prediabetic postmenopausal women | Muscle NAD+ signaling increased | Improved muscle insulin sensitivity (single small study) |
| Yi 2023 — NMN, 300–900 mg/day | Healthy middle-aged adults | Blood NAD+ rose dose-dependently | Better 6-minute walk & some questionnaire scores at higher doses |
| Brakedal 2022 (NADPARK) — NR, 1000 mg/day | Early Parkinson's disease | Brain & blood NAD+ increased | Mild clinical signal; framed as hypothesis-generating phase I |
| NR long-COVID RCT 2025 | Adults with long-COVID | NAD+ raised vs placebo | No clear cognitive or symptom benefit over placebo |
Two entries deserve a note. The 2023 NMN trial by Yi and colleagues found a genuine dose-dependent rise in NAD+ alongside modest gains in a six-minute walking test and some subjective scores at the higher amounts studied (PubMed 36482258) — encouraging, but soft endpoints in a healthy group. The NADPARK trial pushed NR into Parkinson's disease and confirmed NAD+ can be raised in the human brain, while the authors themselves treated the clinical readout as preliminary (PubMed 35235774). And the 2025 randomized long-COVID trial of NR is the useful cold shower: it raised NAD+ and still failed to beat placebo on cognition and symptom recovery (PubMed 41357333). Raising the biomarker is not the same as helping the patient.
IV NAD+ therapy: clinic claims vs evidence
Walk into a longevity or wellness clinic and the pitch changes. Instead of pills, you are offered an intravenous NAD+ drip, often for a few hundred dollars a session, marketed for energy, mental clarity, addiction recovery, jet lag, and "anti-aging." The logic is that IV delivery bypasses the gut and pushes NAD+ higher and faster than any capsule.
The delivery claim is plausible. The benefit claim is not supported. A 2024 systematic review in the American Journal of Physiology-Endocrinology and Metabolism evaluated NAD across clinical conditions and found only a small number of randomized trials, with most of the evidence coming from small case series and open-label reports rather than controlled studies (PubMed 37971292). For the headline uses clinics advertise — sharper thinking, more energy, slower aging — there is no rigorous human trial base to point to.
There are three further problems worth stating flatly. First, the pharmacokinetics of infused NAD+ in humans are poorly characterized, so nobody can tell you with confidence where it goes or how long any effect lasts. Second, infusions come with reliable, if usually short-lived, reactions: nausea, flushing, chest tightness, cramping, and discomfort at the infusion site, typically worse when the drip runs fast. Third, IV NAD+ is not an FDA-approved therapy for any of these indications; it is offered off-label, and regulators have flagged quality and contamination concerns with compounded NAD injectables. Blood NAD+ may also be a weak proxy for how you are actually aging, which undercuts the premise that pushing it higher must help.
Is NMN legal? Is NAD+ FDA approved?
None of these is an FDA-approved drug. There is no approved NAD+, NMN, or NR medicine for longevity, energy, or any wellness use. That is the single most important regulatory fact, and it applies equally to the capsule and the drip.
Their supplement status is where it gets tangled, and NMN is a genuinely unusual case. NR has been sold as a dietary ingredient for years with an accepted new-dietary-ingredient notification behind it. NMN's path was messier. The FDA initially acknowledged an NMN notification in 2022, then reversed and took the position that NMN could not be a dietary supplement because it had been authorized for investigation as a drug before being marketed as a supplement — the so-called drug-preclusion clause. After citizen petitions and litigation from the supplement industry, the agency reversed again in 2025, stating that NMN is lawful for use in dietary supplements. The practical upshot for a 2026 reader is that NMN and NR are both sold legally as supplements in the United States, but supplements are not reviewed for efficacy before sale, and label accuracy in this category is uneven.
IV NAD+ sits outside that framework entirely. It is not an approved drug and not a supplement; it is an infusion administered off-label under a clinician's discretion. If you want the broader map of how approval status, prescription rules, and the research-chemical gray market differ across compounds, our guide on whether peptides are legal and how regulatory status works applies the same framework to the peptides NAD+ is so often shelved beside.
NAD+, NMN and NR side effects reported in trials
For oral precursors, the published safety record over weeks to months is reassuring. Randomized trials of NR in overweight adults reported no serious adverse events and no flushing at the doses tested, with NR metabolized cleanly (PubMed 31278280). The first human NMN study, in healthy Japanese men, found a single oral dose was safely metabolized with no meaningful problems in clinical parameters (PubMed 31685720). Where mild effects appear, they are unremarkable: nausea, indigestion, diarrhea, headache, and occasional flushing — the last more associated with the older B3 forms niacin and nicotinamide than with NR or NMN.
Two honest caveats belong here. The trials are short. Most run 8 to 24 weeks, so multi-year safety at the doses people actually take for longevity is simply unknown. And there is an unresolved theoretical debate about NAD+ and cancer, because some tumors are metabolically hungry for NAD+; this is a laboratory-level concern that has not shown up as harm in the human trials, but it is a reason the "more is better" assumption should not be taken on faith. For IV NAD+, add the infusion-related reactions described above and the quality risks of compounded injectables.
NMN vs NR: which precursor is better?
This is the comparison the market wants a clean answer to, and the science does not provide one. Both NMN and NR reliably raise blood NAD+, and no adequately powered head-to-head human trial has shown one to be clearly superior for a hard health outcome. They sit one step apart on the same salvage pathway, so it would be surprising if the difference were large.
What separates them today is track record, not proven potency. NR has more published human trials and a longer, less contested regulatory history in the United States. NMN has the more magnetic marketing story, an association with high-profile aging labs, and the single best functional result so far in the prediabetic-women insulin study — balanced against equally rigorous trials where its precursor cousin moved the biomarker but not the body. If a vendor tells you one is decisively better, they are ahead of the evidence. Direct comparison trials are only now emerging.
The same discipline applies to the peptides people stack alongside NAD+. Mitochondria-focused compounds like SS-31 (elamipretide) and the mitochondrial-derived peptide MOTS-c share NAD+'s "cellular energy and aging" narrative and its thin human evidence base, and nootropic peptides such as semax attract the same subjective, easy-to-misattribute reports.
How long does NMN or NR take to work?
If "work" means raising NAD+, the answer is fast. Human trials detect higher blood NAD+ within days and a stable elevation by about two weeks, which then holds as long as you keep taking the precursor. That part is dependable and reproducible.
If "work" means feeling or measuring a benefit, there is no reliable timeline, because the benefit itself is not reliable. The functional endpoints that did move in trials — insulin sensitivity, a walking test — were assessed over roughly 8 to 12 weeks of daily use. Anti-aging in any meaningful sense has no established schedule because it has not been demonstrated in people. Any product promising visible age reversal in a matter of weeks is describing hope, not data.
That uncertainty is exactly why a written record beats memory here. When the expected effect is subtle, delayed, and heavily shaped by expectation, the only way to tell a real change from a placebo response is a consistent, dated log — what you took, at what dose, and how you actually felt, tracked over months rather than recalled. Our guide on how to track peptides and supplements covers that discipline, and it matters more for NAD+ than for almost anything else on the longevity shelf, precisely because the effects are so easy to imagine.
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme built from two nucleotides joined by phosphate groups. It has no amino acids and no peptide bonds, so it is not a peptide. Its supplement precursors, NMN and NR, are a nucleotide and a form of vitamin B3, not peptides either. NAD+ is grouped with peptides mainly because it is sold on the same longevity shelves and by the same wellness clinics.
Do NMN and NR supplements actually work?
It depends on what you mean by work. Human trials consistently show that oral NMN and NR raise NAD+ levels in blood, often by 40 to 100 percent within two weeks. What they have not shown consistently is a clear payoff in strength, endurance, metabolism, or aging. Some studies found isolated benefits, such as improved insulin sensitivity or walking distance, while others found none. The evidence for real-world results is still thin.
Is NMN legal and is it FDA approved?
No NMN, NR, or NAD+ product is an FDA-approved drug. NR has long been sold as a dietary ingredient. NMN's status was contested: the FDA excluded it from the supplement definition in 2022 because it had been studied as a drug first, then reversed course in 2025 and stated that NMN is lawful in dietary supplements. IV NAD+ is not FDA approved and is offered off-label by clinics.
Is IV NAD+ therapy worth it?
The evidence does not support the marketing. A systematic review of NAD in clinical conditions found only a handful of randomized trials, with most claims resting on small case series rather than rigorous studies. IV infusion raises NAD+ faster than pills, but there is no good proof that this translates into more energy, better cognition, or slower aging. Infusions also carry reactions such as nausea, flushing, and chest tightness, and are not FDA approved.
What are the side effects of NMN and NR?
In human trials of a few weeks to several months, oral NMN and NR have been generally well tolerated at the doses studied, with no serious drug-related adverse events reported. The mild effects that do appear include nausea, indigestion, diarrhea, headache, and occasional flushing, which is more common with the related B3 forms niacin and nicotinamide. Long-term safety over years has not been established, and IV NAD+ adds infusion-related reactions.
NMN vs NR: which raises NAD+ better?
Both reliably raise blood NAD+, and no head-to-head trial has shown one to be clearly superior for health outcomes. NR has more published human trial data and a clearer regulatory footing in the United States. NMN has attracted more consumer attention and some positive early studies. Because they sit next to each other on the same salvage pathway, the practical difference for most measured endpoints so far is small.
How long does NMN or NR take to work?
Blood NAD+ climbs quickly. Trials typically detect higher NAD+ within days and a stable rise by about two weeks. Any functional change, where it appears at all, is usually measured over 8 to 12 weeks of daily use. There is no established timeline for anti-aging benefits because those benefits have not been reliably demonstrated in people, so claims of visible age reversal on any schedule outrun the data.
Can you raise NAD+ without supplements?
Yes. NAD+ is made in the body from dietary vitamin B3 (niacin, nicotinamide, and NR found in foods) through the salvage and de novo pathways. Exercise, fasting, and caloric restriction have each been reported to support NAD+ metabolism in research settings. Whether any of these raises NAD+ enough to change how you age is unproven, but they carry benefits that expensive precursor pills do not.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- NAD+ in aging, metabolism, and neurodegeneration — PubMed 26785480
- CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism — PubMed 27304511
- NAD+ metabolism and its roles in cellular processes during ageing — PubMed 33353981
- NAD+ in Brain Aging and Neurodegenerative Disorders — PubMed 31577933
- Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence — PubMed 29514064
- Nicotinamide riboside is uniquely and orally bioavailable in mice and humans — PubMed 27721479
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults — PubMed 29599478
- Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults — PubMed 31278280
- Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures — PubMed 31412242
- Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men — PubMed 31685720
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women — PubMed 33888596
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, dose-dependent clinical trial — PubMed 36482258
- The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update — PubMed 37619764
- The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease — PubMed 35235774
- Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review — PubMed 37971292
- Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial — PubMed 41357333